Snehal Patel Buys 2,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,500 shares of the business’s stock in a transaction that occurred on Friday, March 22nd. The stock was bought at an average price of $19.98 per share, for a total transaction of $49,950.00. Following the acquisition, the chief executive officer now owns 5,347,777 shares of the company’s stock, valued at $106,848,584.46. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Snehal Patel also recently made the following trade(s):

• On Wednesday, March 20th, Snehal Patel purchased 1,500 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $17.68 per share, for a total transaction of $26,520.00.
• On Monday, March 4th, Snehal Patel purchased 4,100 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $13.03 per share, for a total transaction of $53,423.00.
• On Thursday, February 15th, Snehal Patel purchased 12,700 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $11.07 per share, for a total transaction of $140,589.00.

Greenwich LifeSciences Trading Down 1.6 %

NASDAQ:GLSI opened at $20.00 on Thursday. The firm’s fifty day simple moving average is $12.71 and its 200 day simple moving average is $10.85. Greenwich LifeSciences, Inc. has a twelve month low of $7.58 and a twelve month high of $21.44.

Institutional Trading of Greenwich LifeSciences

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in shares of Greenwich LifeSciences by 100.2% during the 1st quarter. Bank of America Corp DE now owns 6,213 shares of the company’s stock valued at $122,000 after buying an additional 3,110 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter valued at $90,000. Goldman Sachs Group Inc. bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter valued at $104,000. Citigroup Inc. bought a new stake in shares of Greenwich LifeSciences during the 1st quarter valued at $172,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Greenwich LifeSciences during the 4th quarter valued at $194,000. Institutional investors own 4.16% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of Greenwich LifeSciences in a report on Wednesday, February 28th.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.